HPV-FASTER: broadening the scope for prevention of HPV-related cancer

FX Bosch, C Robles, M Diaz, M Arbyn… - Nature reviews Clinical …, 2016 - nature.com
Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer
enormous potential for cancer prevention, notably prevention of cervical cancer. The …

[HTML][HTML] Clinical trials of human papillomavirus vaccines and beyond

M Lehtinen, J Dillner - Nature reviews Clinical oncology, 2013 - nature.com
Human papillomavirus (HPV) is the most common sexually transmitted infectious agent; its
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo …

LL Villa, RLR Costa, CA Petta, RP Andrade… - The lancet …, 2005 - thelancet.com
Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim …

J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón… - The Lancet, 2007 - thelancet.com
Background The aim of this interim analysis of a large, international phase III study was to
assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate …

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final …

J Paavonen, P Naud, J Salmerón, CM Wheeler… - The Lancet, 2009 - thelancet.com
Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was
immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections …

[HTML][HTML] Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck

J Mork, AK Lie, E Glattre, S Clark… - … England Journal of …, 2001 - Mass Medical Soc
Background Oncogenic human papillomaviruses (HPVs), especially HPV type 16 (HPV-16),
cause anogenital epithelial cancers and are suspected of causing epithelial cancers of the …

[HTML][HTML] Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes

D Mesher, K Soldan, M Lehtinen… - Emerging infectious …, 2016 - ncbi.nlm.nih.gov
We analyzed human papillomavirus (HPV) prevalences during prevaccination and
postvaccination periods to consider possible changes in nonvaccine HPV genotypes after …

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised …

M Lehtinen, J Paavonen, CM Wheeler… - The lancet …, 2012 - thelancet.com
Background Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate
endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy …

Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case‐control study in the Nordic countries

P Tuohimaa, L Tenkanen, M Ahonen… - … journal of cancer, 2004 - Wiley Online Library
Vitamin D inhibits the development and growth of prostate cancer cells. Epidemiologic
results on serum vitamin D levels and prostate cancer risk have, however, been inconsistent …

[HTML][HTML] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

LL Villa, RLR Costa, CA Petta, RP Andrade… - British Journal of …, 2006 - nature.com
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …